Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is set to issue its quarterly earnings data before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.51) earnings per share. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Trading Up 1.6 %

AGIO stock opened at $46.83 on Wednesday. The firm has a market cap of $2.66 billion, a P/E ratio of -7.41 and a beta of 0.75. Agios Pharmaceuticals has a 12-month low of $20.04 and a 12-month high of $53.28. The stock’s 50 day simple moving average is $44.69 and its 200 day simple moving average is $41.98.

Analysts Set New Price Targets

AGIO has been the subject of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Scotiabank assumed coverage on Agios Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $51.00 target price on the stock. Finally, Raymond James restated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $52.00.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.